Azole-based inhibitors of AKT/PKB for the treatment of cancer.
Zeng, Q., Allen, J.G., Bourbeau, M.P., Wang, X., Yao, G., Tadesse, S., Rider, J.T., Yuan, C.C., Hong, F.T., Lee, M.R., Zhang, S., Lofgren, J.A., Freeman, D.J., Yang, S., Li, C., Tominey, E., Huang, X., Hoffman, D., Yamane, H.K., Fotsch, C., Dominguez, C., Hungate, R., Zhang, X.(2010) Bioorg Med Chem Lett 20: 1559-1564
- PubMed: 20137943 
- DOI: 10.1016/j.bmcl.2010.01.067
- Primary Citation of Related Structures:  
3L9L, 3L9M, 3L9N - PubMed Abstract: 
Through a combination of screening and structure-based rational design, we have discovered a series of N(1)-(5-(heterocyclyl)-thiazol-2-yl)-3-(4-trifluoromethylphenyl)-1,2-propanediamines that were developed into potent ATP competitive inhibitors of AKT. Studies of linker strand-binding adenine isosteres identified SAR trends in potency and selectivity that were consistent with binding interactions observed in structures of the inhibitors bound to AKT1 and to the counter-screening target PKA ...